UB Paderborn / Katalog / Suche / in CDI

Racial Disparities in Religious Beliefs and Colon Cancer Detection

Annals of epidemiology, 2012-09, Vol.22 (9), p.664-664

2012

Volltextzugriff (PDF)

Absence of nonprimate hepacivirus-related genomes in blood donors seroreactive for hepatitis C virus displaying indeterminate blot patterns

Journal of viral hepatitis, 2014-11, Vol.21 (11), p.e164-e166

2014

Volltextzugriff (PDF)

Calgb/Swog 80405: Analysis of Patients Undergoing Surgery As Part of Treatment Strategy

Annals of oncology, 2014-09, Vol.25, p.v1

2014

Volltextzugriff (PDF)

Post-treatment CEA Values, and CEA Trends at the Time of Uncertain Post-treatment Imaging, Have Prognostic Value after Combined Modality Therapy for Rectal Cancer

International journal of radiation oncology, biology, physics, 2010, Vol.78 (3), p.S313-S313

2010

Volltextzugriff (PDF)

Intra-Operative Radiation Therapy and Surgical Excision for Locally Recurrent Gastrointestinal Cancers: Initial Results of a Single-Institution Registry

International journal of radiation oncology, biology, physics, 2021-11, Vol.111 (3), p.e28-e29

2021

Volltextzugriff (PDF)

Combined Modality Therapy for Rectal Cancer: Analysis of Potential Differences in Disease Presentation, Treatment Adherence, and Treatment Outcome According to Race

International journal of radiation oncology, biology, physics, 2010, Vol.78 (3), p.S198-S198

2010

Volltextzugriff (PDF)

Contrasting HCV and HIV seroepidemiology in 11 years of blood donors screening in Brazil

Transfusion medicine (Oxford, England), 2017-08, Vol.27 (4), p.286-291

2017

Volltextzugriff (PDF)

Pharmacogenomics‐Based Point‐of‐Care Clinical Decision Support Significantly Alters Drug Prescribing

Clinical pharmacology and therapeutics, 2017-11, Vol.102 (5), p.859-869

2017

Volltextzugriff (PDF)

O-12 NCI9673 (Part B): A multi-institutional ETCTN randomized phase II study of nivolumab with or without ipilimumab in refractory, metastatic squamous cell carcinoma of the anal canal

Annals of oncology, 2023-06, Vol.34, p.S185-S186

2023

Volltextzugriff (PDF)

Combination Therapy of Imatinib Mesylate and Interferon-α Demonstrates Minimal Activity and Significant Toxicity in Metastatic Renal Cell Carcinoma: Results of a Single-Institution Phase II Trial

Clinical genitourinary cancer, 2006-03, Vol.4 (4), p.275-280

2006

Volltextzugriff (PDF)

CALGB/SWOG 80405: Phase III Trial of Irinotecan/5-FU/Leucovorin (FOLFIRI) or Oxaliplatin/5-FU/Leucovorin (MFOLFOX6) with Bevacizumab (BV) or Cetuximab (CET) for Patients (PTS) with KRAS Wild-Type (WT) Untreated Metastatic Adenocarcinoma of the Colon

Annals of oncology, 2014-06, Vol.25, p.ii112-ii112

2014

Volltextzugriff (PDF)

O-022A multi-institutional phase 2 study of single agent nivolumab in previously treated metastatic squamous cell carcinoma of the anal canal (SCCA)

Annals of oncology, 2016-06, Vol.27 (suppl_2), p.ii126-ii126

2016

Volltextzugriff (PDF)

O-022 A multi-institutional phase 2 study of single agent nivolumab in previously treated metastatic squamous cell carcinoma of the anal canal (SCCA)

Annals of oncology, 2016-06, Vol.27, p.ii126

2016

Volltextzugriff (PDF)

Race and Subset Analyses in Clinical Trials: Time to Get Serious About Data Integration

JNCI : Journal of the National Cancer Institute, 2011-10, Vol.103 (20), p.1486-1488

2011

Volltextzugriff (PDF)

411 POSTER A phase I, open-label, dose-escalation study of the safety and pharmacology of MetMAb, a monovalent antagonist antibody to the receptor c-Met, administered IV in patients with locally advanced or metastatic solid tumors

European journal of cancer supplements, 2008, Vol.6 (12), p.129-129

2008

Volltextzugriff (PDF)

Cost-effectiveness of Maintenance Capecitabine and Bevacizumab for Metastatic Colorectal Cancer

JAMA oncology, 2019-02, Vol.5 (2), p.236

2019

Volltextzugriff (PDF)

Calgb/Swog 80405: Phase III Trial of Irinotecan/5-Fu/Leucovorin (Folfiri) or Oxaliplatin/5-Fu/Leucovorin (Mfolfox6) with Bevacizumab (Bv) or Cetuximab (Cet) for Patients (Pts) with Expanded Ras Analyses Untreated Metastatic Adenocarcinoma of the Colon Or Rectum (Mcrc)

Annals of oncology, 2014-09, Vol.25, p.v1

2014

Volltextzugriff (PDF)

Relationship between components of the comprehensive geriatric assessment (CGA), chemotherapy dose intensity, and overall survival in a colorectal cancer (CRC) cohort age 65 and older

Journal of clinical oncology, 2011-05, Vol.29 (15_suppl), p.9000-9000

2011

Volltextzugriff (PDF)

Compliance to adjuvant hormone therapy for black and white women with breast cancer

Journal of clinical oncology, 2011-05, Vol.29 (15_suppl), p.1555-1555

2011

Volltextzugriff (PDF)

A prospective paired survey of oncologist and patient attitudes toward therapeutic cancer clinical trial (CT) enrollment in a diverse academic health center patient population

Journal of clinical oncology, 2010-05, Vol.28 (15_suppl), p.6120-6120

2010

Volltextzugriff (PDF)

Exploring racial differences in outcome for metastatic colorectal cancer: Results from a large prospective observational cohort study (BRiTE)

Journal of clinical oncology, 2010-05, Vol.28 (15_suppl), p.e14039-e14039

2010

Volltextzugriff (PDF)

Understanding differences in the receipt of chemotherapy between African-American (AA) and white (W) patients with stage III colon cancer

Journal of clinical oncology, 2007-06, Vol.25 (18_suppl), p.6568-6568

2007

Volltextzugriff (PDF)

Dasatinib (D) in previously treated metastatic colorectal cancer (mCRC) patients: A phase II trial of the University of Chicago phase II consortium

Journal of clinical oncology, 2011-02, Vol.29 (4_suppl), p.506-506

2011

Volltextzugriff (PDF)

Utilization and costs of non-evidence-based (non-EBM) antineoplastic agents in patients with metastatic colon cancer (mCC)

Journal of clinical oncology, 2011-05, Vol.29 (15_suppl), p.6002-6002

2011

Volltextzugriff (PDF)

Evaluating psychosocial and belief differences in a diverse racial and socioeconomic cancer population

Journal of clinical oncology, 2010-05, Vol.28 (15_suppl), p.6036-6036

2010

Volltextzugriff (PDF)

Menü

Weitere Dienste

Einstellungen

Racial Disparities in Religious Beliefs and Colon Cancer Detection

Absence of nonprimate hepacivirus-related genomes in blood donors seroreactive for hepatitis C virus displaying indeterminate blot patterns

Calgb/Swog 80405: Analysis of Patients Undergoing Surgery As Part of Treatment Strategy

Post-treatment CEA Values, and CEA Trends at the Time of Uncertain Post-treatment Imaging, Have Prognostic Value after Combined Modality Therapy for Rectal Cancer

Intra-Operative Radiation Therapy and Surgical Excision for Locally Recurrent Gastrointestinal Cancers: Initial Results of a Single-Institution Registry

Combined Modality Therapy for Rectal Cancer: Analysis of Potential Differences in Disease Presentation, Treatment Adherence, and Treatment Outcome According to Race

Contrasting HCV and HIV seroepidemiology in 11 years of blood donors screening in Brazil

Pharmacogenomics‐Based Point‐of‐Care Clinical Decision Support Significantly Alters Drug Prescribing

O-12 NCI9673 (Part B): A multi-institutional ETCTN randomized phase II study of nivolumab with or without ipilimumab in refractory, metastatic squamous cell carcinoma of the anal canal

Combination Therapy of Imatinib Mesylate and Interferon-α Demonstrates Minimal Activity and Significant Toxicity in Metastatic Renal Cell Carcinoma: Results of a Single-Institution Phase II Trial

CALGB/SWOG 80405: Phase III Trial of Irinotecan/5-FU/Leucovorin (FOLFIRI) or Oxaliplatin/5-FU/Leucovorin (MFOLFOX6) with Bevacizumab (BV) or Cetuximab (CET) for Patients (PTS) with KRAS Wild-Type (WT) Untreated Metastatic Adenocarcinoma of the Colon

O-022A multi-institutional phase 2 study of single agent nivolumab in previously treated metastatic squamous cell carcinoma of the anal canal (SCCA)

O-022 A multi-institutional phase 2 study of single agent nivolumab in previously treated metastatic squamous cell carcinoma of the anal canal (SCCA)

Race and Subset Analyses in Clinical Trials: Time to Get Serious About Data Integration

411 POSTER A phase I, open-label, dose-escalation study of the safety and pharmacology of MetMAb, a monovalent antagonist antibody to the receptor c-Met, administered IV in patients with locally advanced or metastatic solid tumors

Cost-effectiveness of Maintenance Capecitabine and Bevacizumab for Metastatic Colorectal Cancer

Calgb/Swog 80405: Phase III Trial of Irinotecan/5-Fu/Leucovorin (Folfiri) or Oxaliplatin/5-Fu/Leucovorin (Mfolfox6) with Bevacizumab (Bv) or Cetuximab (Cet) for Patients (Pts) with Expanded Ras Analyses Untreated Metastatic Adenocarcinoma of the Colon Or Rectum (Mcrc)

Relationship between components of the comprehensive geriatric assessment (CGA), chemotherapy dose intensity, and overall survival in a colorectal cancer (CRC) cohort age 65 and older

Compliance to adjuvant hormone therapy for black and white women with breast cancer

A prospective paired survey of oncologist and patient attitudes toward therapeutic cancer clinical trial (CT) enrollment in a diverse academic health center patient population

Exploring racial differences in outcome for metastatic colorectal cancer: Results from a large prospective observational cohort study (BRiTE)

Understanding differences in the receipt of chemotherapy between African-American (AA) and white (W) patients with stage III colon cancer

Dasatinib (D) in previously treated metastatic colorectal cancer (mCRC) patients: A phase II trial of the University of Chicago phase II consortium

Utilization and costs of non-evidence-based (non-EBM) antineoplastic agents in patients with metastatic colon cancer (mCC)

Evaluating psychosocial and belief differences in a diverse racial and socioeconomic cancer population

Suchergebnisse filtern